Company Tiziana Life Sciences Ltd

Equities

TLSA

BMG889121031

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.74 ^USD	+1.65%		-26.00%	+32.14%

Jun. 11	Tiziana Says FDA Accepts Fast Track Label Submission For Multiple Sclerosis Treatment	MT
Jun. 11	FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis	CI

Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.

Number of employees: 9

Managers	Title	Age	Since
Gabriele Cerrone CEO	Chief Executive Officer	52	98-02-10
Keeren Shah DFI	Director of Finance/CFO	47	-
Vaseem Palejwala CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Matthew Davis COO	Chief Operating Officer	-	22-06-30
Paul Spencer IRC	Investor Relations Contact	-	22-11-30
William Clementi PRN	Corporate Officer/Principal	-	23-08-31

Members of the board	Title	Age	Since
John Brancaccio BRD	Director/Board Member	76	20-06-30
Willy Simon BRD	Director/Board Member	72	15-10-31
Gabriele Cerrone CEO	Chief Executive Officer	52	98-02-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	194,612,289	63,738,859 ( 32.75 %)	0	32.75 %

Name	Equities	%	Valuation
Gabriele Cerrone 37.73 %	38,890,635	37.73 %	39 M $
Geode Capital Management LLC 0.2094 %	215,825	0.2094 %	215 825 $
HSBC Bank Plc 0.1593 %	164,226	0.1593 %	164 226 $
Morgan Stanley Capital Services LLC 0.1224 %	126,138	0.1224 %	126 138 $
Ausdal Financial Partners, Inc. 0.0540 %	55,700	0.0540 %	55 700 $
EWA LLC 0.0536 %	55,300	0.0536 %	55 300 $
Zhang Financial LLC 0.0505 %	52,060	0.0505 %	52 060 $
UBS Securities LLC 0.0303 %	31,244	0.0303 %	31 244 $
Bank of America, NA (Charlotte, North Carolina) 0.0210 %	21,686	0.0210 %	21 686 $
Barclays Bank Plc 0.0170 %	17,500	0.0170 %	17 500 $

Name	Equities	%	Valuation
ACCUSTEM SCIENCES, INC. 11.80%	1,337,970	11.80%	628,846 $

Tiziana Life Sciences Ltd.

14/15 Conduit Street

W1S 2XJ, London

http://www.tizianalifesciences.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
TIZIANA LIFE SCIENCES LTD	+32.14%	75.12M
MODERNA, INC.	+40.80%	53.67B
IQVIA HOLDINGS INC.	-8.05%	38.76B
LONZA GROUP AG	+35.79%	38.86B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research